Jiangsu Hengrui Pharmaceuticals Co.,Ltd

600276

CNE0000014W7

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 2026-01-12			5-day change	1st Jan Change
63.85 ^CNY	+0.11%		+7.18%	+7.18%

Jan. 07	Hengrui Pharmaceuticals Wins China Marketing Approval for Gastric Cancer Drug	MT
Jan. 07	Jiangsu Hengrui Pharmaceuticals says unit got notice from NMPA for retlirafusp alfa injection	RE

Hengrui Medicine Gets Marketing Approval for Synthetic Vitamin D

Published on 11/24/2025 at 10:00 pm EST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Jan. 07	Hengrui Pharmaceuticals Wins China Marketing Approval for Gastric Cancer Drug	MT
Jan. 07	Jiangsu Hengrui Pharmaceuticals says unit got notice from NMPA for retlirafusp alfa injection	RE
Jan. 05	Hengrui Pharmaceuticals Gets Regulatory Nod for Prostate Cancer Clinical Trials	MT
Jan. 05	Hengrui Pharmaceuticals Gets Approval for Combined Obesity Drug Trials	MT
Jan. 04	HUTCHMED Begins Phase 3 Trial of Surufatinib and Camrelizumab to Treat Pancreatic Cancer	MT
Jan. 04	Tranche Update on Jiangsu Hengrui Pharmaceuticals Co.,Ltd's Equity Buyback Plan announced on August 20, 2025.	CI
Dec. 30	Hengrui Pharma Gets Nod to Trial Six Drugs	MT
Dec. 30	Hengrui Pharma Gets Nod to Trial HRS-6257 Tablets	MT
Dec. 28	Hengrui Pharmaceuticals Licenses Kidney Drug to Hansoh Pharma in Related-Party Deal	MT
Dec. 28	Jiangsu Hengrui Pharmaceuticals Co.,Ltd Enters into A License Agreement	CI
Dec. 21	Jiangsu Hengrui Pharmaceuticals Co.,Ltd(SEHK:1276) added to S&P Global BMI Index	CI
Dec. 21	Jiangsu Hengrui Pharmaceuticals Co.,Ltd(SEHK:1276) added to FTSE All-World Index	CI
Dec. 15	JPMorgan Chase & Co's long position in H-shares of Jiangsu Hengrui Pharmaceuticals increases to 8.29%, HKEX says	RE
Dec. 15	Hengrui Medicine's Unit Gets Nod to Trial Tumor Drug	MT
Dec. 15	Hengrui Medicine's Unit Gets Nod to Trial RSS0343 Tablets	MT
Dec. 15	Hengrui Medicine's Unit Gets Nod to Trial HRS9531 Injection	MT
Dec. 12	Morgan Stanley's long position in H-shares of Jiangsu Hengrui pharmaceuticals decreases to 2.76% on Dec 8 - HKEX	RE
Dec. 08	Hengrui Medicine's 20 Drugs Included in China's Reimbursement Drug List	MT
Dec. 08	Jiangsu Hengrui Medicine Gets Inclusion in China's Medical Insurance Catalog	MT
Dec. 02	Hengrui Medicine Gets Regulatory Acceptance for Anesthetic Marketing Application	MT
Nov. 27	Hengrui Medicine Gets China Approval for Multiple Drug Trials	MT
Nov. 27	Hengrui Medicine Gets Regulatory Nod for Vitiligo Drug Trials	MT
Nov. 25	Hengrui Medicine Gets Clinical Trial Approval for Tumor Monotherapy; Shares Up 3%	MT
Nov. 25	Hengrui Medicine Gets Clinical Trial Approval for Tumor Treatment	MT
Nov. 24	Hengrui Medicine Says Emavusitinib Marketing Application Accepted by Chinese Drug Regulator	MT

Chart Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Duration

Period

Chart Jiangsu Hengrui Pharmaceuticals Co.,Ltd

600276: Dynamic Chart

Jiangsu Hengrui Medicine Co., Ltd. specializes in the research, development, manufacture and marketing of pharmaceutical products. The activity is organized primarily around 5 families of products: - anti-tumor drugs (No. 1 Chinese); - Anesthetic drugs; - contrast agents: used in medical imaging; - anti-inflammatory drugs; - drugs for the treatment of cardiovascular diseases.

Employees

20,238

Sector

Pharmaceuticals

Calendar

Mar. 25 - Q4 2025 Earnings Release

More about the company